Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...
4h
Hosted on MSNCelebrity weight loss drug to be offered in Colchester pharmacyA COLCHESTER pharmacy boss is “delighted” to offer a weight loss drug which has been used by celebrities through a new ...
A new study reveals a novel connection between aging of visceral adipose tissue and brain health. These findings are ...
Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.
Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside. Metsera is also viewed as a ...
Metsera Inc. (MTSR), a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of weight-loss drugs in development, using both the hormones already used in existing ...
Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range ...
Higher adherence to the Mediterranean diet reduced the risk of obesity-related cancers, but not in the way researchers ...
Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...
The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable ...
Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...
Eli Lilly & Co. said Tuesday that it has launched new doses of its obesity treatment drug and reduced its prices. The pharmaceutical company said it has launched 7.5 and 10 milligram single dose vials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results